$Axovant Sciences Ltd(AXON)$
2018年1月9日，Axovant发布了一份新闻稿更正了研究药物Nelotanserin的相关数据。
On January 9, 2018, Axovant issued a press release correcting data related to Axovant’s investigational drug nelotanserin previously reported by Axovant in its January 8, 2018 press release. In Axovant’s pilot Phase 2 Visual Hallucination study, the post-hoc subset analysis of patients with a baseline Scale for the Assessment of Positive Symptoms - Parkinson’s Disease score of greater than 8.0 was misreported. The Company correctly reported that nelotanserin treatment at 40 mg for two weeks followed by 80 mg for two weeks resulted in a 1.21 point improvement, but the p-value should have been reported as 0.531, unadjusted, instead of 0.011, unadjusted.
A copy of the press release issued January 9, 2018 is filed herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
https://www.sec.gov/Archives/edgar/data/1636050/000110465918001375/a18-2345_28ka.htm
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
关注我们